PATENT CLAIM ANALYSIS

Application Number: 16320723
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-05
Patent Classification: ["514", "263200"]

Abstract:
The invention relates to a xanthine derivative defined by chemical formula I or a salt thereof, its use as a medicament, especially for use in the treatment of serotonin-related diseases or disorders, and a pharmaceutical preparation comprising the xanthine derivative. The novel xanthine compounds are capable of inhibiting tryptophan hydroxylases (TPH) involved in the biosynthesis of serotonin and are effective in influencing the serotonin level in the body.

Claim (Index 12):
Xanthine derivative for use according to  claim 11 , wherein the serotonin-related disease or disorder comprises or consists of serotonin syndrome; bone diseases comprising osteoporosis, osteoporosis pseudoglioma syndrome (OPPG), osteopenia, osteogenesis imperfecta, osteomalacia, renal osteodystrophy, faulty bone formation or resorption, Paget's disease, fractures and broken bones, and bone metastasis; immunological diseases comprising systemic sclerosis and transplant rejection; Pulmonary diseases comprising chronic obstructive pulmonary disease (COPD), pulmonary hypertension, and asthma; gastrointestinal diseases comprising abdominal pain, carcinoid syndrome, celiac disease, constipation, Crohn's disease, diarrhea, emesis, anorectal disorders, bloating, dyspepsia, gallbladder disorders, irritable bowel syndrome, lactose intolerance, MEN types I and II, nausea, Ogilvie's syndrome, pancreatic insufficiency, somatization disorder, sphincter of Oddi disorders, ulcerative colitis, and Zollinger-Ellison Syndrome; cancer comprising carcinoid tumours, pheochromocytoma, carcinoma of prostate, lung, bladder, intestine, breast, liver and ovary; vascular diseases comprising thrombosis, atherosclerosis, aortic aneurysm, coronary artery disease, peripheral artery disease, CREST syndrome, migraine; inflammatory diseases comprising pancreatitis, hepatitis, and asthma; metabolic diseases comprising non-alcoholic fatty liver disease, obesity, diabetes, and metabolic syndrome; psychiatric diseases comprising major depression, bipolar disorder, schizophrenia, and hypoactive sexual desire disorder.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 99.0
- Lexical Diversity: 1.47059
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15552556', '13389993', '12474838', '09738376', '11542166']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7970683567820587
- 35 USC 102 Novelty (BERT): 0.5772394306120955
- Combined Prediction Score: 0.7750854641650624
- Mean Citation Score: 385.525688
- Max Citation Score: 580.3537
- Similarity Product: 362.4943479992272

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test